Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Physical Review Letters
|
January 7, 2021
Nanowire Transistors with Bound-Charge Engineering
Raphaël J Prentki, Mohammed Harb, Lei Liu, et al.
The American Journal of Surgical Pathology
|
January 23, 2018
NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors
Brendan C Dickson, Yun-Shao Sung, Marc K Rosenblum, et al.
Therapeutic Advances in Medical Oncology
|
June 30, 2023
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
Mélina Boutin, James T Topham, Harriet Feilotter, et al.
Journal for Immunotherapy of Cancer
|
December 4, 2024
Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
Lucy X Ma, Emma Titmuss, Jonathan M Loree, et al.
JAMA Network Open
|
December 5, 2023
Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial
Eric X Chen, Jonathan M Loree, Emma Titmuss, et al.
JAMA Oncology
|
May 8, 2020
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study
Eric X Chen, Derek J Jonker, Jonathan M Loree, et al.
Nature Communications
|
August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Daniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Clinical and Translational Medicine
|
May 1, 2021
Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer
Karen Gambaro, Maud Marques, Suzan McNamara, et al.
Nature Communications
|
March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma
Daniel J Renouf, James T Topham, Jonathan M Loree, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma
James T Topham, Haley M Beckmann, Joanna M Karasinska, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Physical Review Letters
|
January 7, 2021
Nanowire Transistors with Bound-Charge Engineering
Raphaël J Prentki, Mohammed Harb, Lei Liu, et al.
The American Journal of Surgical Pathology
|
January 23, 2018
NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors
Brendan C Dickson, Yun-Shao Sung, Marc K Rosenblum, et al.
Therapeutic Advances in Medical Oncology
|
June 30, 2023
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
Mélina Boutin, James T Topham, Harriet Feilotter, et al.
Journal for Immunotherapy of Cancer
|
December 4, 2024
Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
Lucy X Ma, Emma Titmuss, Jonathan M Loree, et al.
JAMA Network Open
|
December 5, 2023
Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial
Eric X Chen, Jonathan M Loree, Emma Titmuss, et al.
JAMA Oncology
|
May 8, 2020
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study
Eric X Chen, Derek J Jonker, Jonathan M Loree, et al.
Nature Communications
|
August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Daniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Clinical and Translational Medicine
|
May 1, 2021
Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer
Karen Gambaro, Maud Marques, Suzan McNamara, et al.
Nature Communications
|
March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma
Daniel J Renouf, James T Topham, Jonathan M Loree, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma
James T Topham, Haley M Beckmann, Joanna M Karasinska, et al.
Page
of 2